Previous 10 | Next 10 |
MALVERN, Pa., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a pharmaceutical company focused on innovative products for hospital and related settings, today announced the closing of its previously announced public of...
MALVERN, Penn., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced the pricing of a public offering of an aggregate of 1,042,787 sh...
MALVERN, Pa., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on innovative products for hospital and related settings, today announced that the Company’s Board of Directors has approved a 1-for-40 reverse stock split of its common shares (...
Baudax Bio press release ( NASDAQ: BXRX ): Q3 GAAP EPS of -$2.47. Revenue of $0.24M (-14.3% Y/Y). For further details see: Baudax Bio GAAP EPS of -$2.47, revenue of $0.24M
BX 1000 Phase II Trial Underway BX 2000 Dose Escalation Study Progressing ANJESO ® Vials Sold to End Users Up 16% Third Quarter Year-Over-Year USPTO Issues Note of Allowance for additional Orange Book Listable ANJESO ® Patent ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: ventdusud / Shutterstock.com Welcome back and get ready for another week of trading with the biggest pre-market stock movers for Monday! We’ve got clinical trial data, reverse stock splits, as well as...
MALVERN, Pa., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on innovative products for acute care settings, today announced that Gerri Henwood, the Company’s President and Chief Executive Officer, will present at the 24 th Ann...
MALVERN, Pa., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced the closing of its previously announced public offering of ...
3 Active Penny Stocks to Watch Right Now With an interesting day of trading penny stocks ahead of us, there is a lot for investors to know. As a result, understanding what’s going on with penny stocks is more important than ever. It’s also important to consider that pe...
Priced $6.2 million offering. Late Monday, Baudax announced the pricing of its public offering. The offering of 11.819 million shares of common or pre-funded warrants at a public offering price of $0.525 per share were sold as a unit. Each share or warrant unit included a Series A-1 warrant to...
News, Short Squeeze, Breakout and More Instantly...
Baudax Bio Inc. Company Name:
BXRX Stock Symbol:
NYSE Market:
Evolv Technologies Holdings Inc. (EVLV) is expected to report $-0.14 for Q4 2023 The Lion Electric Company (LEV) is expected to report $-0.1 for Q4 2023 Fisker Inc. Class A (FSR) is expected to report $-0.2 for Q4 2023 Y-mAbs Therapeutics Inc. (YMAB) is expected to report $-0.19 for Q...
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Baudax Bio Inc. (BXRX) is expected to report $-0.53 for Q3 2023